Page 118 - EJMO-9-3

Eurasian Journal of Medicine

and Oncology

ORIGINAL RESEARCH ARTICLE
Comparative efficacy and safety of Zercepac®

plus pyrotinib versus Zercepac® plus
pertuzumab in combination with chemotherapy

as neoadjuvant therapy for HER2-positive breast
cancer: A retrospective study

1
3
Hong Gao , Jiali Lei 2 , Zhaohua Gui , and Shengying Wang *
1
1 Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Anhui University of
Chinese Medicine (Anhui Provincial Hospital of Chinese Medicine), Hefei, Anhui, China
2 Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China
Pharmaceutical University, Nanjing, Jiangsu, China
3 Division of Life Sciences and Medicine, Department of Pathology, The First Affiliated Hospital of
University of Science and Technology of China, Hefei, Anhui, China

Abstract

Introduction: HER2-positive breast cancer needs better neoadjuvant options.
*Corresponding author:
Shengying Wang Pyrotinib (Py) with trastuzumab biosimilar may offer an alternative to dual
(wangshengying61@163.com) blockade. Objective: This study analyzed the short-term efficacy and safety of
Citation: Gao H, Lei J, Gui Z, Zercepac®, a trastuzumab biosimilar, combined with either Py or pertuzumab and
Wang S. Comparative efficacy and chemotherapy in neoadjuvant therapy for HER2-positive breast cancer. It also
safety of Zercepac plus pyrotinib compared the efficacy and safety of Zercepac®-pyrotinib-chemotherapy versus
®
versus Zercepac plus pertuzumab
®
in combination with chemotherapy Zercepac®-pertuzumab-chemotherapy regimens.
as neoadjuvant therapy for Methods: Clinical data from 62 HER2-positive breast cancer patients who underwent
HER2-positive breast cancer: A neoadjuvant therapy with Zercepac® combined with Py or pertuzumab and
retrospective study. Eurasian J Med
Oncol. 2025;9(3):110-121. chemotherapy at Anhui Cancer Hospital (February 2021 to December 2023) were
doi: 10.36922/EJMO025100044 retrospectively analyzed. Efficacy and safety were compared among TCbHP (29 cases),
Received: March 4, 2025 TCbHPy (8 cases), THP (9 cases), and TCbH (16 cases) groups. Statistical methods were
used to identify factors influencing total pathological complete response (tpCR).
1st revised: April 20, 2025 Results: Among the 62 patients, 45 (72.6%) had invasive breast cancer, 11 (17.7%)
2nd revised: April 25, 2025 had invasive carcinomas with intraductal components, five (8.1%) had invasive
Accepted: April 28, 2025 carcinomas with ductal carcinoma in situ, and one (1.6%) had invasive carcinoma
with mucinous features. Age and advanced clinical stage were independent risk
Published online: May 14, 2025 factors for tpCR (p<0.001). The TCbHPy group showed comparable efficacy to TCbHP
Copyright: © 2025 Author(s). (p=0.25). Alopecia (91.9%) was the most common adverse event. Diarrhea incidence
This is an Open-Access article was significantly higher in TCbHPy than in TCbHP (p<0.001); however, no grade 4
distributed under the terms of the
Creative Commons Attribution diarrhea occurred, and triple antidiarrheal therapy reduced its severity to grade 1.
License, permitting distribution, Conclusion: Zercepac® is effective and safe in neoadjuvant therapy for HER2-positive
and reproduction in any medium, breast cancer. Py (≥400 mg) may improve tpCR rates, with diarrhea as the main
provided the original work is
properly cited. adverse effect. TCbHPy regimen demonstrated non-inferior efficacy to TCbHP.
Publisher’s Note: AccScience
Publishing remains neutral with Keywords: Zercepac ; Trastuzumab; Pertuzumab; Pyrotinib; HER2-positive breast cancer;
®
regard to jurisdictional claims in
published maps and institutional Neoadjuvant therapy; Pathological complete response; Adverse events
affiliations.

Volume 9 Issue 3 (2025) 110 doi: 10.36922/EJMO025100044